New drug combo aims to control rare blood cancer in older adults
NCT ID NCT07206264
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study tests a combination of chemotherapy (bendamustine) and targeted therapy (orelabrutinib plus an anti-CD20 antibody) as a first treatment for mantle cell lymphoma. It includes 45 adults aged 60 or older who cannot or choose not to have a stem cell transplant. The goal is to see if this approach improves how long the cancer stays under control, using PET scans and MRD tests to guide treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
-
Hebei Medical University Tumor Hospital
Shijiazhuang, Hebei, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.